Food and drug administration (FDA) center for radiological health (cdrh) risk analysis of emerging technologies for medical device safety COR: karina kuhn
Ended Awarded Last action
- Contract number
- 75F40124F80325
- Awardee
-
The Mitre Corporation UEI DMHDNDCPWUD1
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $417,733
Award facts
- Contract value 100% obligated
- $417,733.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $417,733 |
About this award
The Food and Drug Administration's Center for Radiological Health awarded a delivery order to The Mitre Corporation valued at $417,733 on September 19, 2024, for risk analysis of emerging technologies for medical device safety. This cost-plus-fixed-fee contract, which requires Cost of Contracting and Cost of Services approval, extends through December 31, 2025, and will be performed in Silver Spring, Maryland. The engagement represents an extension of the period of performance for Mitre's ongoing work supporting the FDA's efforts to evaluate and assess safety risks associated with new and emerging medical device technologies.
This delivery order is issued under a larger indefinite delivery vehicle, indicating Mitre's established role as a trusted technical partner to the FDA. As a federally funded research and development center, Mitre provides scientific and technical support across multiple federal agencies, with particular expertise in systems engineering, data analytics, and technology assessment. The contract carries no set-aside designation, consistent with Mitre's status as a large non-profit organization. Through this engagement, Mitre will continue delivering analytical and research capabilities to help the FDA manage regulatory challenges posed by innovative medical device technologies.
Quick answers
Who was awarded contract 75F40124F80325?
75F40124F80325 was awarded to The Mitre Corporation by Food and Drug Administration (Department of Health and Human Services) on September 19, 2024.
How much is contract 75F40124F80325 worth?
The government has obligated $417,733 on 75F40124F80325.
Is contract 75F40124F80325 an order under another contract?
Yes. 75F40124F80325 is a delivery order under 75FCMC23D0004, an indefinite delivery contract.
Was contract 75F40124F80325 competed?
The extent of competition for 75F40124F80325 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award